Improving Outcomes in Oral Cancer pp 105-115 | Cite as
Factors Affecting Response and Survival in Radiotherapy
Abstract
We are investigating the different variables that can potentially affect tumor response to radiation therapy. These factors can be tumor-specific, patient-specific, therapy-specific, or a combination of these variables. Noteworthy factors include extranodal extension, tumor microenvironment, time to adjunctive radiation therapy, tumor volume, margin status, adjunctive concurrent chemotherapy, and fractionation schedule/dose. This chapter sheds light on how the previously mentioned factors can potentially impact the efficacy of radiation treatment on locoregional recurrence, overall survival, and disease-free specific survival as a treatment modality for oral cancer.
Keywords
Radiation therapy Efficacy Extranodal extension Margin status Fractionation dose Tumor volume Locoregional control ChemotherapyReferences
- 1.Lavaf A, et al. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer. 2008;112(3):535–43.PubMedCrossRefPubMedCentralGoogle Scholar
- 2.Kao J, et al. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys. 2008;71(2):362–70.PubMedCrossRefPubMedCentralGoogle Scholar
- 3.Sanguineti G, Forastiere AA. Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer. Nat Clin Pract Oncol. 2008;5:694.PubMedCrossRefPubMedCentralGoogle Scholar
- 4.Perri F, et al. Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck. 2015;37(5):763–70.PubMedCrossRefPubMedCentralGoogle Scholar
- 5.Silva P, et al. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clin Otolaryngol. 2007;32(5):337–45.PubMedCrossRefPubMedCentralGoogle Scholar
- 6.Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57(1):39–43.PubMedCrossRefPubMedCentralGoogle Scholar
- 7.Allal AS, et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20(5):1398–404.PubMedCrossRefPubMedCentralGoogle Scholar
- 8.La TH, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1335–41.PubMedPubMedCentralCrossRefGoogle Scholar
- 9.Jeong J, et al. Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Radiother Oncol. 2014;111(3):340–7.PubMedPubMedCentralCrossRefGoogle Scholar
- 10.Buffa FM, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res. 2004;10(11):3745–54.CrossRefGoogle Scholar
- 11.Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol. 2012;22(2):108–18.PubMedCrossRefPubMedCentralGoogle Scholar
- 12.Alsner J, Sorensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol. 2001;59(2):179–85.PubMedCrossRefPubMedCentralGoogle Scholar
- 13.Somers KD, et al. Frequent p53 mutations in head and neck cancer. Cancer Res. 1992;52(21):5997–6000.PubMedPubMedCentralGoogle Scholar
- 14.Csuka O, et al. Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer. Pathol Oncol Res. 1997;3(3):204–10.PubMedCrossRefPubMedCentralGoogle Scholar
- 15.Haffty BG, Glazer PM. Molecular markers in clinical radiation oncology. Oncogene. 2003;22(37):5915–25.PubMedCrossRefPubMedCentralGoogle Scholar
- 16.Sittel C, et al. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol. 1999;35(6):583–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 17.Jacob R, et al. Heterogeneity of squamous cell carcinomas of the head and neck-analysis of tumor biologic factors and proliferation rates. Laryngoscope. 1996;106(9):1170–5.PubMedCrossRefPubMedCentralGoogle Scholar
- 18.Raybaud H, et al. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma. Int J Oral Maxillofac Surg. 2000;29(1):36–41.PubMedCrossRefPubMedCentralGoogle Scholar
- 19.Ang KK, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350–6.PubMedPubMedCentralGoogle Scholar
- 20.Fu KK, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16.PubMedCrossRefPubMedCentralGoogle Scholar
- 21.Ho AS, et al. Quantitative survival impact of composite treatment delays in head and neck cancer. Cancer. 2018;124(15):3154–62.PubMedPubMedCentralCrossRefGoogle Scholar
- 22.Overgaard J, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362(9388):933–40.PubMedCrossRefPubMedCentralGoogle Scholar
- 23.González Ferreira JA, et al. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature. Rep Pract Oncol Radiother. 2015;20(5):328–39.PubMedPubMedCentralCrossRefGoogle Scholar
- 24.Harris JP, et al. Association of survival with shorter time to radiation therapy after surgery for US patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2018;144(4):349–59.PubMedPubMedCentralCrossRefGoogle Scholar
- 25.Graboyes EM, et al. Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. Cancer. 2017;123(24):4841–50.PubMedPubMedCentralCrossRefGoogle Scholar
- 26.Sanguineti G, et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys. 2005;61(3):762–71.PubMedCrossRefPubMedCentralGoogle Scholar
- 27.Lacas B, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–37.PubMedPubMedCentralCrossRefGoogle Scholar
- 28.Baujat B, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010;12:Cd002026.Google Scholar
- 29.Radoi L, Luce D. A review of risk factors for oral cavity cancer: the importance of a standardized case definition. Community Dent Oral Epidemiol. 2013;41(2):97–109, e78–91.PubMedCrossRefPubMedCentralGoogle Scholar
- 30.Browman GP, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993;328(3):159–63.PubMedCrossRefPubMedCentralGoogle Scholar
- 31.Chen AM, et al. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys. 2011;79(2):414–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 32.Rabinovitch R, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head Neck. 2006;28(4):287–96.PubMedCrossRefPubMedCentralGoogle Scholar
- 33.Pai PC, et al. Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int J Radiat Oncol Biol Phys. 2012;83(1):e93–e100.PubMedCrossRefPubMedCentralGoogle Scholar
- 34.Amit M, et al. Improvement in survival of patients with oral cavity squamous cell carcinoma: an international collaborative study. Cancer. 2013;119(24):4242–8.PubMedCrossRefPubMedCentralGoogle Scholar
- 35.Zhang H, et al. Survival outcomes of patients with advanced oral cavity squamous cell carcinoma treated with multimodal therapy: a multi-institutional analysis. J Otolaryngol Head Neck Surg. 2013;42:30.PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Iyer NG, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599–607.PubMedCrossRefPubMedCentralGoogle Scholar
- 37.Daly ME, et al. Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. Int J Rad Oncol Biol Phys. 2011;80(5):1412–22.CrossRefGoogle Scholar
- 38.Parsons JT, et al. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys. 1997;39(1):137–48.PubMedCrossRefPubMedCentralGoogle Scholar
- 39.Hinerman RW, et al. Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35-year experience. Head Neck. 2004;26(11):984–94.PubMedCrossRefPubMedCentralGoogle Scholar
- 40.Bernier J, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52.PubMedPubMedCentralCrossRefGoogle Scholar
- 41.Ooishi M, et al. Patterns of failure after postoperative intensity-modulated radiotherapy for locally advanced and recurrent head and neck cancer. Jpn J Clin Oncol. 2016;46(10):919–27.PubMedCrossRefPubMedCentralGoogle Scholar